Pfizer signs 5-year exclusive marketing deal with Cipla for 4 brands

Marquee JV announcedStrategic Transactions View source PDF Explain this filing

PFIZER · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹5100.00

prior close

₹5095.80

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+1.3%-1.5% vs market

Pharmaceuticals peers, median of 153sector+0.7%-0.9% vs sector

On the reaction day the stock moved 1.5 pts less than Nifty Smallcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.1

15m

-0.0

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2+1.3-1.5+0.7-0.9

Next day

+0.6+2.3-1.7+1.3-0.7

-0.5+2.7-3.3+1.4-2.0

-1.1+2.8-3.9+1.4-2.5

-1.0+2.6-3.6+0.7-1.7

-2.8+2.1-4.8+0.0-2.8

-2.6+3.0-5.6+0.7-3.3

15d

-5.2-0.6-4.6-1.0-4.2

-8.4-1.0-7.4-1.8-6.6

-2.0-1.3-0.8-4.0+2.0

-7.5-8.9+1.4-10.2+2.7

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Pfizer Limited has signed a 5-year exclusive supply and marketing agreement with Cipla Limited for four brands: Corex Dx, Corex LS, Dolonex, and Neksium. Cipla will market and distribute these medicines across India while Pfizer continues to manufacture and supply them. No upfront cash is involved. The deal is expected to lead to some reduction in Pfizer's field force, with related costs to be disclosed in upcoming financial results. Both companies say the partnership aims to widen patient reach and depth across India.

Likely market impact

Pfizer hands marketing of legacy brands to Cipla for 5 years; field force cuts likely, with restructuring costs to be flagged in upcoming results.